2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.57: Survival of Metastatic Lung Adenocarcinoma Among Women in a Single Colombian Cancer Center

PP01.57: Survival of Metastatic Lung Adenocarcinoma Among Women in a Single Colombian Cancer Center

Pdf Summary

This study investigated the survival of women with metastatic lung adenocarcinoma at the National Cancer Institute in Colombia from 2018 to 2022. It focuses on the clinical and molecular characteristics of the patients and their association with overall survival. The retrospective analysis included data from 54 women with stage IV lung adenocarcinoma, with a median age of 68 years (IQR 56-74). The investigation found that a significant portion of these patients did not undergo essential molecular profiling, particularly for ALK and PDL1, which limits the applicability of targeted treatments. <br /><br />Key findings include that 39.6% of patients had a history of tobacco use, and most were at an ECOG performance status of 2. Regarding treatment outcomes, women with stage IVA disease had a median survival of 28.3 months, while those with stage IVB experienced a shorter median survival of 7.4 months. Treatment with targeted therapy resulted in a median survival of 28.3 months, chemoimmunotherapy yielded 27.2 months, chemotherapy 14.6 months, and best supportive care had the lowest at 1.7 months. <br /><br />Of the women diagnosed, 35.2% had an EGFR mutation, and first-line treatment for these patients predominantly involved targeted therapies. Similarly, for those with ALK rearrangements, targeted therapy was employed but not universally due to incomplete molecular testing. The study highlighted that while targeted therapies improve survival rates, their reach remains limited due to the lack of comprehensive molecular testing. Overall, the research underscores the need for better molecular profiling to optimize treatment strategies and improve survival outcomes for women with metastatic lung adenocarcinoma.

Asset Subtitle

Carlos Carvajal

Keywords

metastatic lung adenocarcinoma

National Cancer Institute

Colombia

clinical characteristics

molecular profiling

ALK

PDL1

EGFR mutation

targeted therapy

survival outcomes